Extended Data Figure 8: Concentration-dependent ALK inhibition in ALKATI-, wild-type ALK-, ALKF1174L-, and EML4–ALK-expressing Ba/F3 cells.
From: Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
a, b, Cell viability assay of Ba/F3 cells, either in the presence or absence of IL-3 (1 ng ml−1), expressing the indicated ALK isoforms and treated with the indicated doses of ALK inhibitors ceritinib (a) and TAE-684 (b). Cell viability was measured after 72 h of drug treatment. Error bars, mean ± s.e.m.; n = 3 biological replicates. c–e, Representative immunoblots of Ba/F3 cells stably expressing wild-type ALK (c), ALKF1174L (d), or EML4–ALK (e) and treated with increasing concentration of crizotinib for 2 h. See Supplementary Fig. 1 for uncropped blots.
